Creative Medical Technology Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CELZ research report →
Companywww.creativemedicaltechnology.com
Creative Medical Technology Holdings, Inc. , a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility.
- CEO
- Timothy Warbington
- IPO
- 2015
- Employees
- 4
- HQ
- Phoenix, AZ, US
Price Chart
Valuation
- Market Cap
- $5.86M
- P/E
- -1.46
- P/S
- 1952.70
- P/B
- 1.38
- EV/EBITDA
- -0.02
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -894.97%
- Op Margin
- -198049.63%
- Net Margin
- -192066.27%
- ROE
- -88.50%
- ROIC
- -96.88%
Growth & Income
- Revenue
- $6.00K · -45.45%
- Net Income
- $-5,995,008 · -9.13%
- EPS
- $-2.52 · 32.08%
- Op Income
- $-6,142,814
- FCF YoY
- -10.47%
Performance & Tape
- 52W High
- $6.25
- 52W Low
- $1.50
- 50D MA
- $2.12
- 200D MA
- $2.60
- Beta
- 1.85
- Avg Volume
- 50.05K
Get TickerSpark's AI analysis on CELZ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 18, 25 | Finger Michael H. | sell | 750 |
| Feb 19, 25 | Finger Michael H. | sell | 750 |
| Jun 28, 23 | Warbington Timothy | buy | 200 |
| Jun 27, 23 | Warbington Timothy | buy | 200 |
| Jun 27, 23 | Warbington Timothy | buy | 300 |
| Jun 27, 23 | Warbington Timothy | buy | 300 |
| Nov 22, 22 | Warbington Timothy | buy | 200 |
| Nov 22, 22 | Warbington Timothy | buy | 9,800 |
| Nov 21, 22 | Warbington Timothy | buy | 5,000 |
| Nov 21, 22 | Warbington Timothy | buy | 10,000 |
Our CELZ Coverage
We haven't published any research on CELZ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CELZ Report →